Q-omics provides the consensus-scored XRCC3 profile across patient tissues and cancer cell-line models. XRCC3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, XRCC3 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, XRCC3 RNA expression shows 19,941 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where XRCC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for XRCC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes XRCC3 survival associations across molecular data types. XRCC3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible XRCC3 RNA expression–survival associations across cancer types. High XRCC3 expression shows unfavorable associations in ACC, KIRC, LIHC, UVM, LGG and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for XRCC3 RNA expression.
This table summarizes XRCC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for XRCC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. XRCC3 shows higher tumor expression in HNSC, COAD, KIRP, BLCA, KIRC and LIHC. The HNSC box plot shows higher XRCC3 RNA expression in tumor versus normal tissue (log2 FC = +1.191, t-test p < 0.001).
This table shows molecular features associated with XRCC3 in patient tissues and cancer cell lines. In patient samples, XRCC3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, XRCC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
